R
Rolf Sauer
Researcher at University of Erlangen-Nuremberg
Publications - 434
Citations - 25897
Rolf Sauer is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Radiation therapy & Breast cancer. The author has an hindex of 66, co-authored 434 publications receiving 23906 citations.
Papers
More filters
Journal ArticleDOI
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
Rolf Sauer,Heinz Becker,Werner Hohenberger,Claus Rödel,Christian Wittekind,Rainer Fietkau,Peter Martus,Jörg Tschmelitsch,Eva Hager,Clemens F. Hess,Torsten Liersch,Heinz Schmidberger,Rudolf Raab +12 more
TL;DR: Preoperative chemoradiotherapy, as compared with postoperative cheMoradi therapy, improved local control and was associated with reduced toxicity but did not improve overall survival.
Journal ArticleDOI
Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years
Rolf Sauer,Torsten Liersch,Susanne Merkel,Rainer Fietkau,Werner Hohenberger,Clemens F. Hess,Heinz Becker,Hans-Rudolf Raab,Marie-Therese Villanueva,Helmut Witzigmann,Christian Wittekind,Tim Beissbarth,Claus Rödel +12 more
TL;DR: In this paper, the authors reported long-term results with a median follow-up of 134 months, where they found a difference of 10% in 5-year overall survival as the primary end point.
Journal ArticleDOI
Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal Cancer
Claus Rödel,Peter Martus,Thomas Papadoupolos,László Füzesi,Martin Klimpfinger,Rainer Fietkau,Torsten Liersch,Werner Hohenberger,Rudolf Raab,Rolf Sauer,Christian Wittekind +10 more
TL;DR: In this exploratory analysis, complete ( TRG 4) and intermediate pathologic response (TRG 2 + 3) suggested improved DFS after preoperative CRT, and TRG assessment should be implemented in pathologic evaluation and prospectively validated in further studies.
Journal ArticleDOI
Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer
David M. Brizel,Todd H. Wasserman,Michael Henke,Vratislav Strnad,Volkar Rudat,Alain Monnier,François Eschwege,Jay Zhang,Lesley Russell,Wolfgang Oster,Rolf Sauer +10 more
TL;DR: With and without amifostine, 2-year local-regional control, disease-free survival, and overall survival were 58% versus 63, 53% versus 57%, and 71% versus 66%, respectively, while Antitumor treatment efficacy was preserved.
Journal ArticleDOI
Combined-Modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-Term Results
Claus Rödel,Gerhard G. Grabenbauer,Reinhard Kühn,Thomas Papadopoulos,J. Dunst,Martin Meyer,Karl M. Schrott,Rolf Sauer +7 more
TL;DR: TUR with RCT is a reasonable option for patients seeking an alternative to radical cystectomy and Ideal candidates are those with early-stage and unifocal tumors, in whom a complete TUR is accomplished.